Many individuals start to see weight loss results within the first few weeks of treatment
Bovendien verloor 89% tot 91% van de patinten 5% of meer van hun gewicht, wat als klinisch significant wordt beschouwd voor het verbeteren van de metabolische gezondheid
Li QX, Gao H, Guo YX et al (2021) GLP-1 and underlying beneficial actions in alzheimers disease, hypertension, and NASH
Wegovy injections are approved for adults and adolescents aged 12 and older who are diagnosed with obesity, though they are sometimes prescribed to those overweight with related medical conditions
Addressing both metabolic and hormonal imbalances is essential for long-term symptom relief, and Oana Healths comprehensive care aims to do just that
The cardiovascular effects of retatrutide are an area of active investigation